as One of the Best Abstracts Presented at the Leading Diabetic Foot Global Conference
The number of biotech companies completing an IPO has swelled this year and Adynxx aims to join their ranks—but through an alternate path. The pain drug developer has agreed to combine operations with publicly traded Alliqua Biomedical … Under the merger agreement announced Friday, shares of Adynxx will convert into Alliqua (NASDAQ: ALQA) stock, leaving former Adynxx shareholders owning approximately 86 percent of the combined company. That company will have the Adynxx name and will be led by the current Adynnx management team. It will be headquartered in San Francisco, where Adynxx is currently based … read more